Local association of *Trypanosoma cruzi* chronic infection foci and enteric neuropathic lesions at the tissue micro-domain scale

**Archie A. Khan**, Harry C. Langston, Fernanda C. Costa, Francisco Olmo, Martin C. Taylor, Conor J. McCann, John M. Kelly, Michael D. Lewis

1 Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, United Kingdom, 2 Stem Cells and Regenerative Medicine, University College London, Institute of Child Health, London, United Kingdom

* michael.lewis@lshtm.ac.uk

**Abstract**

Digestive Chagas disease (DCD) is an enteric neuropathy caused by *Trypanosoma cruzi* infection. The mechanism of pathogenesis is poorly understood and the lack of a robust, predictive animal model has held back research. We screened a series of mouse models using gastrointestinal tracer assays and *in vivo* infection imaging systems to discover a subset exhibiting chronic digestive transit dysfunction and significant retention of faeces in both sated and fasted conditions. The colon was a specific site of both tissue parasite persistence, delayed transit and dramatic loss of myenteric neurons as revealed by whole-mount immunofluorescence analysis. DCD mice therefore recapitulated key clinical manifestations of human disease. We also exploited dual reporter transgenic parasites to home in on locations of rare chronic infection foci in the colon by *ex vivo* bioluminescence imaging and then used fluorescence imaging in tissue microdomains to reveal co-localisation of infection and enteric nervous system lesions. This indicates that long-term *T. cruzi*-host interactions in the colon drive DCD pathogenesis, suggesting that the efficacy of anti-parasitic chemotherapy against chronic disease progression warrants further pre-clinical investigation.

**Author summary**

Chagas disease (American trypanosomiasis) is caused by the protozoan parasite *Trypanosoma cruzi*. Chagas disease has two types, the cardiac form and the digestive form; some patients have symptoms of both. How the parasite causes digestive disease is poorly understood. It is known that damage to the gut’s nervous system is an important factor, but it has been unclear exactly where and when this damage occurs during the course of an infection and also why only a subset of infected people suffer from this outcome. We studied infections in mice and found certain combinations of strains of parasites and mice that exhibited symptoms similar to human digestive Chagas patients, including a problem with peristalsis that localised specifically to the colon. Using parasites that were genetically engineered to emit both bioluminescent and fluorescent light, we tracked infections over
time and were able to analyse rare infected cells deep within the muscle tissue of the wall of the colon. We found evidence of damaged neurons in the same location as these infection foci over 6 months after initial infection. Our results show that digestive Chagas disease probably develops as a result of chronic infection and inflammation, which potentially changes approaches to treatment.

Introduction

Chagas disease (CD) is caused by infection with the protozoan parasite Trypanosoma cruzi, which affects approximately 6 million people. There are two principal forms of CD, cardiac and digestive. The most prevalent cardiac presentations include myocarditis, fibrosis, arrhythmias, microvascular abnormalities, progressive heart failure and sudden death [1]. Cardiac CD has been the subject of intensive experimental research and many predictive animal models are available to support translation into the clinic. Human digestive CD (DCD) is characterised by progressive dilatation and dysfunction of sections of the GI tract [2,3]. Symptoms include achalasia, abdominal pain, constipation and faecaloma. Eventually, massive organ dilatation results in megasyndromes, usually of the colon and/or oesophagus. Dilatation is associated with loss of enteric neurons leading to peristaltic paralysis and smooth muscle hypertrophy. Treatments are largely limited to dietary and surgical interventions [4]. The lack of a robust small animal model of enteric CD has been a major block on basic and translational research.

Of symptomatic CD patients, ~65% have cardiomyopathy, 30% enteropathy and 5% have both, with digestive disease most common in Bolivia, Chile, Argentina and Brazil [1]. Anti-parasitic chemotherapy has not been considered justifiable for T. cruzi-positive individuals with digestive symptoms, but normal heart function, as no clinical trials have addressed treatment efficacy in the context of digestive outcomes [5]. Challenges for clinical trials include the highly variable and unpredictable clinical outcomes of T. cruzi infection, the extended time frame for disease development and, especially in the context of DCD, a paucity of experimental data [6]. Molecular and cellular explanations of DCD pathogenesis also lag far behind the advances made for Chagas cardiomyopathy.

The lack of progress in developing treatments for DCD may also be connected to the idea that megasyndromes result from irreversible enteric denervation, specifically during the acute phase of infection [7,8], in which anti-parasitic inflammatory responses are thought to cause iNOS-dependent collateral damage to neurons, leading to aganglionosis [7,9]. Further age-related nerve degeneration was posited to gradually unmask these parasite-driven losses, leading to progressive organ dysfunction on a timescale of years to decades [7]. However, the frequent detection of T. cruzi and signs of active inflammation in oesophageal and colonic tissues from patients circumstantially suggests that chronic parasite persistence may contribute to disease development [10–17]. Furthermore, experimental bioluminescence imaging and tissue PCR studies in mice revealed that the GI tract is a major long-term reservoir of T. cruzi infection [18–22]. Adult enteric neurogenesis has been described in response to chemically-mediated tissue injury [23] and in the steady state [24]. A series of advances has also highlighted previously unappreciated levels of interconnectedness between the gut’s immune and nervous systems [25–27]. We therefore sought to develop murine DCD models suitable to address the hypothesis that host-parasite interactions in the chronically infected gut might impact continuously on the enteric nervous system (ENS) and musculature to drive disease pathogenesis.
Here, we studied a series of parasite and mouse strain combinations to identify several models with significant digestive motility dysfunction. Using a combination of bioluminescence and fluorescence in vivo and ex vivo imaging techniques, we demonstrate that chronic *T. cruzi* persistence, gut motility delay and enteric neuronal damage are co-localised within discrete foci in the colonic muscularis. This indicates that DCD tissue pathology and transit dysfunction are likely driven by *T. cruzi* persistence in the colon and the associated chronic inflammatory response. DCD should therefore be considered as potentially preventable by anti-parasitic chemotherapy. It also opens the way to investigate the molecular and cellular basis of pathogenesis and *T. cruzi* immune evasion.

**Results**

**A subset of *T. cruzi* mouse infection models display chronic digestive transit time delays**

We previously developed a series of mouse models of *T. cruzi* infection based on parasites transgenically expressing the luciferase variant PpyRE9h, which serves as an orange-red light emitting in vivo reporter protein [28]. Host-parasite combinations of BALB/c and C3H/HeN mice and TcVI-CL Brener (CLBR) and TcI-JR strain parasites permit long-term tracking of the course and distribution of infections in individual animals (Fig 1A). These models, which exhibit a spectrum of Chagas heart disease severities [19], were screened for gastrointestinal (GI) transit time delays, a common feature of DCD, by oral feeding of a red dye tracer (carmine). Three of the four host-parasite combinations took significantly longer than control uninfected mice to pass the tracer at acute phase, 3 weeks post-infection (p.i.), and/or at 6 weeks p.i. transition phase (Fig 1B). During the early chronic phase, 12 and 18 weeks p.i., only the TcI-JR-infected C3H mice displayed the delay phenotype, which became markedly more severe as the infection developed into the later chronic phase at 24 and 30 weeks p.i. Milder, but still significant transit delay phenotypes also emerged in the other three models.

*T. cruzi* as a species encompasses a high level of genetic diversity structured across six major lineages [29–31]. To test whether and at what level the strong digestive transit delay phenotype in C3H mice was conserved, we tested a further eight *T. cruzi* strains from five lineages (4x TcI, 1x TcII, 1x TcIII, 1x TcIV and 1x TcVI) using the carmine transit assay (S1 Fig). Two more strains were identified showing evidence of delayed transit: TcI-SN3 and TcVI-Peru. This type of pathology is therefore a relatively rare, strain-specific trait in *T. cruzi*. It occurs in both TcI and TcVI strains, but is not conserved within lineages.

**Parasite persistence within the GI tract**

We selected the TcI-JR-infected C3H mouse as the most suitable model of experimental chronic DCD. The transit time delay in these animals (Fig 1B) did not show a correlation with the overall parasite burden, which dropped by approximately two orders of magnitude from the acute peak to the level seen in the chronic phase (Fig 1A). Much of the bioluminescence signal in whole animal imaging derives from parasites in the skin [18,19], so we quantified organ-specific parasite loads using ex vivo imaging at 3, 6 and 30 weeks p.i. (Fig 2A). Parasitism was consistently detected in the GI tract, in foci distributed from the stomach to the rectum, being relatively more intense in the stomach and large intestine compared to the small intestine (Fig 2A and 2B). All sites exhibited significantly lower parasite loads in the chronic than acute phase (Fig 2B). There was a positive correlation between endpoint GI parasite loads and the severity of transit delay during the acute phase (3 weeks p.i.), but there were no such quantitative associations in the transition (6 weeks) or chronic (30 weeks) phases (Fig 2C).
Fig 1. Bioluminescence imaging T. cruzi infection models and digestive transit dysfunction screen. A. Ventral images of female C3H/HeN (top panels) and BALB/c mice (bottom panels) representing TcI-JR (1st and 3rd panel) and TcVI-CLBR (2nd and 4th panel) course of infection. Images were captured using in vivo bioluminescence imaging. Overlaid log-scale pseudocolor heat maps are representative of bioluminescence intensity; the log-scale range is indicated in units of radiance. Adjacent line plots show parasite load represented as average bioluminescence of TcI-JR C3H/HeN (n = 10–24), TcVI-CLBR C3H/HeN (n = 5–12), TcI-JR BALB/c (n = 5–12) and Balb/c TcVI-CLBR.
Evidence of chronic GI parasitism was found for other models displaying milder or transient transit dysfunction (C3H –TcVI-CLBR, BALB/c–TcI-JR, BALB/c–TcVI-CLBR, C3H –TcI-SN3, C3H –TcVI-Peru) but also some with normal transit times (C3H –TcI-ArePe, C3H –TcIII-Arma18) (S1 and S2 Figs). Overall the *ex vivo* imaging analyses showed that GI transit time delays (Fig 1) coincided with the persistence of *T. cruzi* in the GI tract (Fig 2) in the principal C3H –TcI-JR model. The relationship between transit dysfunction and gut parasitism,
however, depends on additional factors because (i) there was not a consistent correlation between delay severity and infection intensity over time, and (ii) GI parasite persistence occurs apparently ubiquitously across different mouse-parasite strain combinations (Figs 2 and S2, [19,32]), yet only a subset have a functional DCD phenotype.

Regional dissection of the transit delay phenotype reveals localisation to the colon

The transit time delay seen in symptomatic DCD animals was not explained by differences in body weight or intestine length (S3 Fig). This suggested a functional impairment to peristalsis, as seen in human DCD. Our next aim was to determine the digestive tract region(s) in which the transit time delay was localised. To do this we fed mice with red and green fluorescent tracers (Rhodamine- and FITC-conjugated 70 kDa dextran, respectively) at variable time intervals prior to ex vivo imaging. An interval of 5 minutes was used to test whether stomach emptying was delayed. No significant differences were detected in infected animals compared to controls (Fig 3A), either at 6 or 30 weeks p.i. There was a significant difference in stomach weight at 6 weeks p.i. (Fig 3B), which may indicate increased retention of matter more solid than the tracer.

To measure small intestine dysfunction, we initially analysed tracer transit after 45 minutes and observed a trend for delay in infected mice during the acute but not the chronic phase (Fig 3C). At 3 weeks p.i. there was also significantly increased organ weight (Fig 3D), so we extended analysis at this time point using an increased parasite inoculum and extended the tracer interval time to 60 minutes. Here, we observed evidence of significant small intestine transit delay (Figs 3E and S4).

We next assessed colonic transit using a 90 minute interval after the fluorescent tracer feed. Fluorescence transit appeared similar in infected and control mice at 3 and 6 weeks p.i. (Fig 4A). Unlike the timings used to study transit delay in the upper intestinal tract (Fig 3), the method was less reliable to study the colon in isolation because substantial amounts of dye were still present in the small intestine and we could not quantify any dye that was excreted. Nevertheless, large intestine weights were significantly increased in infected mice at 6 and 30 weeks p.i. (Fig 4B) suggesting a site-specific dysfunction. We therefore employed an alternative assay in which mice were fasted for 4 hours prior to post-mortem analysis of colon lumen contents. T. cruzi infected animals showed significantly greater retention of faeces inside the colon than controls, as shown by pellet counts and both wet and dry total faecal weights, ruling out altered water absorption as an explanation (Fig 4C). The colon-localised transit delay phenotype was highly significant at 6 weeks p.i. and endured into the chronic phase, at 30 weeks p.i. (Fig 4C). By varying the fasting time (0, 2 and 4 h) we showed that this phenotype was maintained irrespective of stomach fullness and showed distal colon faecal impaction developing in T. cruzi infected mice within this timeframe (Fig 4D). The other T. cruzi strains exhibiting signs of total GI transit delay in the carmine assay (SN3, Peru, CLBR) also showed significant retention of faeces after 4 hour fasting, whereas strains with normal carmine transit times did not (S5 Fig). Thus, when GI transit dysfunction occurs in murine chronic T. cruzi infections it is predominantly localised to the colon.

To further investigate whether the observed functional constipation phenotype was accompanied by alterations at the molecular level, we used RT-qPCR to measure transcript abundance for 12 neuronal and inflammatory response genes in colon tissue from chronically infected mice (Fig 4E). Neuron-specific tubulin β-3 (Tubb3) and neuronal nitric oxide synthase (Nos1) genes were strongly downregulated by ~75% compared to naïve control mice. Expression of excitatory substance P and inhibitory vasoactive intestinal peptide (Vip) ENS
neurotransmitters was also decreased, but to a lesser extent. No evidence of altered transcript abundance was found for markers of other enteric neuronal subtypes, tyrosine hydroxylase (Th) and choline acetyltransferase (Chat), tropomyosin receptor kinases (Ntrk1/2/3) or nerve growth factor receptor (Ngrf). Taken together, these data indicate a possible downregulation of the enteric nitrergic transmission associated with GI dysfunction in DCD mice, recapitulating observations in human Chagas megasyndromes as well as other enteric neuropathies [16,33–36].

**Chronic infection foci and enteric neuronal damage at organ and tissue micro-domain scales**

Our next aim was to investigate disease pathogenesis in this model and commonalities with human DCD. Colon tissue from TcI-JR chronically infected mice (> 210 days p.i.) contained significant lymphocytic inflammatory infiltrates that were diffusely and focally distributed in the smooth muscle layers (Fig 5A). Immunohistochemical labelling of the nerve plexuses

---

**Fig 3. Fluorescent tracer imaging assays for stomach emptying and small intestine transit.**

A. Schematic diagram of a mouse receiving oral gavage of a green fluorescent marker, FITC-conjugated 70 kDa dextran, 5 minutes prior to termination to trace stomach emptying delay during infection. Representative images of stomach and small intestine are superimposed with traces of FITC-dextran travelling through stomach into small intestine to show transit difference between control and TcI-JR C3H/HeN infected mice. Linear-scale pseudocolour heat map shows minimum and maximum fluorescence intensity of 70-kDa FITC-dextran. Quantification of FITC-dextran fluorescence in control naïve and TcI-JR C3H/HeN is shown in the adjacent bar plot at 6 (n = 12 per group) and 30 (n = 5 per group) weeks post-infection (p.i.). Fluorescence is expressed as geometric centre which is centre mass of the marker. B. Bar plot shows post-mortem weights of stomach with contents at 6 (n = 7 per group) and 30 (n = 5 per group) weeks p.i. C. Similar schematic diagram and bar plot at 3 (n = 4 per group), 6 (n = 4 per group) and 30 (n = 5 per group) weeks p.i. using a red fluorescent marker, rhodamine-dextran, to target small intestine transit. Linear-scale pseudocolor heat map shows minimum and maximum fluorescence intensity of rhodamine-dextran. D. Small intestine weights shown in bar plot at 3 (n = 4 per group), 6 (n = 7 per group) and 30 (n = 5 per group) weeks p.i. E. Bar plot shows quantification of rhodamine-dextran fluorescence administered 60 minutes before termination of mice at 3 weeks p.i. (n = 4 per group). Dashed lines on bar plots show the GI segment number corresponding to the geometric centre score (0–1 = stomach, 1–10 = small intestine, proximal to distal). Data are expressed as mean ± SEM. Statistical significance was tested using unpaired two-tailed Student’s t test (*P < 0.05).
Fig 4. Evidence of colonic transit dysfunction in experimental digestive Chagas disease model. A. Schematic diagram of a mouse receiving oral gavage of a green fluorescent marker, FITC-conjugated 70 kDa dextran, 90 min prior to termination to trace large intestine transit delay during infection. Representative images of stomach, small and large intestine are superimposed with traces of FITC-dextran travelling through small into large intestine to show transit difference between control and TcI-JR C3H/HeN infected mice. Linear-scale pseudocolor heat map shows minimum and maximum fluorescence intensity of FITC-dextran. Bar plots show quantification of FITC-dextran fluorescence in the large intestine of mice at 3 (n = 4 per group) and 6 (n = 4 per group) weeks post-infection (p.i.). Fluorescence is expressed as geometric centre which is centre mass of the marker. B. Bar plot shows post-mortem weights of large intestine at 3 (n = 4 per group), 6 (n = 7 per group) and 30 (control n = 9, TcI-JR n = 11) weeks p.i. C. Faecal output analyses between control and TcI-JR C3H/HeN infected mice are expressed as faecal pellet count, wet and dry weight, and percentage of water content at 6 (n = 7 per group) and 30 weeks p.i. (n = 5–11 per group). D. Quantification of the effect of different fasting times on faecal output of mice: number of faecal pellets (n = 4–16 per group) and dry faecal weight (n = 4–7 per group). Images of mouse large intestine showing faecal impaction during infection at 30 weeks p.i. after 4 hours fasting compared to control. Scale bar is in cm and mm. Data are expressed as mean ± SEM. Statistical significance was tested using unpaired two-tailed Student’s t test (**P < 0.01; ***P < 0.001, ****P < 0.0001). E. RT-qPCR analysis show log2-fold change in RNA expression of neuronal markers, including pan-neuronal tubulin β-3 (Tubb3), neurotransmitter production (Nos1, Chat, SP, Th, Vip), neuronal growth factor receptors (Ngfr, Ntrk1, Ntrk2, Ntrk3), and non-neuronal NOS isoforms Nos2 and Nos3. RNA was from colon tissue of C3H/HeN naïve control and TcI-JR infected mice (n = 5 per group, biological replicates). Data are expressed as Log2 ΔΔCt ± SD. Dashed line represents mean ± 2SD based on distribution of naïve group values.

https://doi.org/10.1371/journal.ppat.1009864.g004
Fig 5. Effects of chronic *T. cruzi* infection on the enteric nervous system. A. Representative brightfield images of 5 μm thick colon sections stained with haematoxylin-eosin. Samples were cut as transverse cross-sections and images are oriented to show the mucosa to the left of the smooth muscle layers and serosa at the right edge. Inflammatory infiltrates are apparent in infected samples, visible as increased numbers of haematoxylin (purple) stained nuclei (white arrows). Images were taken at 400X magnification, scale bar = 50 μm. Adjacent bar plot shows number of nuclei per field to quantify cellular infiltration in TcI-JR (*n* = 8), TcVI-CLBR (*n* = 10) infected mice compared to naïve controls (*n* = 8). B. Representative brightfield images of 5 μm thick colon sections to detect neuropathy during *T. cruzi* infection detected by immunohistochemistry. Samples were cut as transverse cross-sections and images are oriented to
show the mucosa above the smooth muscle layers and serosa at the lower edge. Sections were labelled with a pan-neuronal antibody (TuJ1) detected as (3,3’-Diaminobenzidine, DAB) chromogen deposits (brown) and counter-stained with haematoxylin (blue), with signal predominantly localising to the myenteric neural plexus situated between the circular and longitudinal muscle layers. Black triangles indicate inflammatory foci, black arrow indicates disorganised TuJ1 distribution in a myenteric ganglion. Images were taken at 200X magnification, scale bar = 50 μm. Adjacent bar plot shows percentage of neuronal tubulin (TuJ1) immunoreactivity in naive control (n = 8), TcI-JR- (n = 8) and TcVI-CLBR (n = 9) infected mice. C. Representative immunofluorescent confocal images of whole-mount colon samples to show the change in anti-HuC/D stained neuronal cell bodies (magenta, top panel) and anti-Tuj1 stained neural network (cyan, middle panel) in the myenteric plexus during T. cruzi infection. Bottom panel shows merged images with DAPI nuclei stain (yellow). White arrows indicate damaged ganglionic neuronal cell bodies. Images were taken at 400X magnification, scale bar = 50 μm. D. Bar plots show number of HuC/D positive neuronal cell bodies per field of view in naive control and TcI-JR infected whole colon samples (left) and from selected regions of the colon: proximal, mid and distal (right; n = 5 per group, all). Quantification of number of ganglia in naive control and TcI-JR infected samples from proximal, mid and distal colon (n = 5 per group). E. Bar plots show number of HuC/D positive neuronal cell bodies per ganglion in naive control and TcI-JR infected whole colon samples (left) and from selected regions of the colon: proximal, mid and distal (right; n = 5 per group, all). All data and images are obtained from matched naive control and infected mice at 30 weeks post-infection. Data are expressed as mean ± SEM. Statistical significance was tested using unpaired two-tailed Student’s t-test (*P < 0.05; **P < 0.01; ***P < 0.001, ****P < 0.0001).

https://doi.org/10.1371/journal.ppat.1009864.g005

within the muscle layers showed that the total amount of neuron-specific tubulin (TuJ1) protein within myenteric ganglia was lower on average in infected mice, but this was not statistically significant (Fig 5B). However, there was a conspicuous spatial disorganisation of TuJ1 in a subset of ganglia, associated with the appearance of anomalous internal acellular structures in these ganglia, which were refractory to common histological dyes (Figs 5B and S6). To investigate this with greater precision, we used whole mount immunofluorescence analysis of the neuronal cell body marker HuC/D. This revealed a dramatic loss of neurons across the proximal, mid and distal colon myenteric plexus (Figs 5C and 5D). This was not a product of a reduced number of ganglia (Fig 5E), rather a highly significant reduction in neurons per ganglion (Fig 5F).

A critical question for rational design of therapies for DCD is whether T. cruzi and the associated host response continues to drive ENS pathology during the chronic phase of infection. At this stage, very few colon cells are infected at any one time and parasite foci are spatiotemporally dynamic, with an intracellular lytic cycle lasting 1–2 weeks before motile trypomastigotes migrate within and between tissues [37]. Thus, any temporal association between infection and ENS damage is likely highly localised and rare at any snapshot in time. Indeed, there was no correlation between chronic endpoint parasite loads in colon regions and the level of local denervation (Fig 6A). We also observed both denervated and intact myenteric ganglia immediately adjacent to each other (Fig 6B). Using dual bioluminescent-fluorescent reporter parasites [38] we were able to visualise rare chronic infection foci at single cell resolution. In most cases, infected cells were early in the proliferative cycle, with 10–50 amastigote forms, and they were located in close proximity to intact enteric nerve fibres (Figs 6C and S7). We also captured a very rare, mature pseudocyst at the point of rupture, with thousands of intracellular parasites and trypomastigote forms escaping the site (Fig 6D). The ENS at the level of this pseudocyst was almost completely ablated, whereas the overlying and laterally adjacent ENS networks were intact (Fig 6E). Taken together, our data demonstrate there is an enduring association, at a highly localised tissue micro-domain scale, between chronic parasitism of the gut wall and ENS lesions.

Discussion

Understanding of the mechanism of DCD pathogenesis remains rudimentary and a lack of experimental tools hampers progress. Post-mortem and biopsy studies of human DCD cases found reduced numbers of enteric neurons and glial cells, often coincident with intact parasites, T. cruzi DNA or antigen and inflammatory infiltrates [2,10–17,39,40]. These are
important insights into late and terminal disease states, but they provide limited information on pathogenesis and relationships with infection load or distribution over time, which can only realistically be studied in animal models. *T. cruzi* infected mice do not develop advanced digestive megasymphyses resembling those in humans, but these are late stage manifestations that usually take many years to develop. Nevertheless, denervation and other features of nascent enteropathy have been described in several mouse models at the histological level [27,41–45]. Delayed transit has also been reported [44,46,47], but neither the GI region involved, nor associations with infection dynamics have been determined. In this study, we present new experimental chronic *T. cruzi* infection imaging models that, crucially, feature co-localised colonic parasite persistence, denervation and delayed transit as a key functional symptom of DCD.

Our data show that the transit delay seen in chronically infected mice predominantly localises to the colon. It should be noted that in humans, digestive disease affects the oesophagus at a similar frequency [40,48], but we did not study this region, mainly because of the technical challenges targeting a functional assay to the murine oesophagus [49]. Also, evidence indicates

Fig 6. Chronic phase colonic *T. cruzi* infection foci and ENS ablation at the tissue micro-domain scale. A. Lack of correlation between end-point colon parasite loads measured by *ex vivo* bioluminescence intensity and degree of colon myenteric plexus denervation. B–E. Whole mount immunofluorescence analysis of colonic muscularis from C3H mice chronically infected with *T. cruzi*. B. HuC/D*+* neuronal cell bodies in colonic myenteric ganglia. Naïve control shows normal morphology; infected mice exhibit adjacent ganglia with both intact (arrowhead) and disrupted (arrow) staining patterns. C. Imaging individual *T. cruzi* (mNeonGreen+) infected cells at early stage of parasite replication cycle adjacent to intact enteric neuron fibres (TuJ1*+*). D–E. Bioluminescence *ex vivo* image (centre)-guided analysis of parasitized and parasite-free tissue micro-domains. D. Mature parasite pseudocyst containing >1000 flagellated trypomastigotes with extracellular trypomastigotes in the local tissue parenchyma (inset) with faint neuronal (TuJ1) staining. E. Z-stack slices at the level of myenteric and submucosal neuronal plexuses showing highly localised loss of TuJ1 staining around the rupturing parasite pseudocyst.

https://doi.org/10.1371/journal.ppat.1009864.g006
the murine oesophagus is not chronically parasitized by *T. cruzi*, or is below the limit of detection for imaging, which might reflect intrinsic anatomical differences between mice and humans in the upper GI tract [50]. The colon, therefore, presents better opportunities for experimental investigation of pathways connecting infection, inflammation and tissue damage. Moreover, enteric neuronal lesions and losses are the central feature in all digestive forms of Chagas disease [51], so the focus on the colon in this model is likely to generate data that can usefully be extrapolated, with due caution, to other GI regions including the oesophagus. There are also wider reasons to be optimistic about the translational value of these murine DCD models. For example, they perform well in predicting the efficacy of anti-parasitic drugs in clinical trials, in terms of both cure of infection and impact on cardiac tissue pathology [52].

The digestive manifestations of Chagas disease predominantly occur in parts of South America where the majority of human *T. cruzi* infections are caused by strains from lineages TcII, TcV and TcVI. Conversely, DCD is apparently far rarer north of the Amazon basin, where most human infections involve TcI. While this geographical association may well be circumstantial, being confounded by eco-epidemiological factors and human population genetic variability [53,54], it is still noteworthy that, in mice, a) GI transit delays were strain and not lineage-specific; and b) the most robust phenotype was caused by a TcI strain. There have been reports of TcI infections in humans with symptoms of digestive disease in Colombia [55,56], and they probably also occur in Venezuela [51] and Mexico [57]. It may be that disease presentation is milder in TcI-endemic areas without progression to megasyndromes and is less likely to be diagnosed. It should also be acknowledged that *in vitro* culture adaptation, genetic manipulation and clonal selection may be factors affecting the strain-specific phenotypes observed in our work. Nevertheless, our data still enable us to conclude that both host and parasite genetics contribute to murine DCD susceptibility. With respect to the host, evidence to date indicates that the digestive tract is probably a ubiquitous reservoir of chronic infection in mice. Disease severity was higher in C3H/HeN than BALB/c mice, a finding previously observed for murine cardiac CD [19], and is consistent with the heterogeneous clinical outcomes observed in humans [1].

A key conclusion is that gut parasitism alone is not sufficient as an explanation for DCD development, though it is likely to be a pre-requisite. The quantity and quality of the host’s immune and tissue repair responses are likely to be central to disease resistance and susceptibility, yet understanding of gut-specific immunity in Chagas disease is mainly limited to descriptions of the general composition of inflammatory infiltrates, which are rich in T and NK cells [2,13,16]. Other outstanding questions include whether the patchiness of ENS damage is explained by the stochastic distribution of parasites, or because particular subsets of ganglia or neurons differ in susceptibility [58], and if so, why? We focussed on analysis of neurons in the myenteric plexus, but it will be important to explore other ENS components, including potential regulatory or neuroprotective functions of enteric glial cells [2,16,59] and broader factors known to influence neuro-immune interactions in the gut, such as host metabolism [60] and microbiota [61].

Analysis of the kinetics of disease development in our main DCD model (TcI-JR infected C3H mice) showed that the intensity of gut parasitism was somewhat correlated with the degree of transit delay around the peak of the acute phase of infection, but this correlation disappeared after the transition to the chronic phase. Transit assays and imaging were done on different days, so it may be that in the acute phase, where parasite loads are very high and more evenly distributed, snapshot parasite load measurements are more representative of wider time frames than they are in the chronic phase, when parasites are more focal and levels fluctuate substantially within and between individual hosts over time [18]. Also, the main effector causing collateral damage to the ENS in the acute phase is likely to be excessive NO
production via iNOS [9], however, the later transition and chronic inflammatory environments are different situations, in that they promote an equilibrium between parasite replication and suppression by host adaptive immunity [62]. Neuro-immune networks in the gut are also highly diverse [63], so additional mechanisms of pathogenesis may come into play during the chronic phase. Investigation of parasite virulence and variability in the host immune response will therefore be required to gain further insight into the determinants of susceptibility and resistance.

In summary, by combining live parasite imaging and gut tracer analyses, we found enduring associations between infection of the colon and local transit impairment at >6 months post-infection, and moreover at the tissue micro-domain scale between single infected cells and ENS lesions. Our results challenge the theory that DCD is a result of collateral damage to the ENS, resulting specifically from the acute inflammatory response against *T. cruzi* [7,64]. They support the interpretation that the presence of *T. cruzi* and inflammatory infiltrates in GI tissues of human DCD patients reflects a long-term association between parasite persistence and disease development [11,13,15]. However, this still does not prove a causal relationship between local infection and pathogenesis, nor the kinetics of the process; this will require elimination of *T. cruzi* at defined time points through anti-parasitic chemotherapy, for example using benznidazole or nifurtimox. More importantly, such experiments will help to predict whether treatment of chronic infections might have the potential to prevent or alleviate DCD in humans.

**Materials and methods**

**Ethics statement**

All *in vivo* experiments were performed in accordance with UK Home Office regulations under the Animal Scientific Procedure Act (ASPA) 1986, within the framework of project license 70/8207 or P9AE04E, and were approved by LSHTM Animal Welfare Ethical Review Board.

**Parasites and infections**

Transgenic clones of *T. cruzi* TcI-JR and TcVI-CLBR constitutively expressing the red-shifted firefly luciferase variant PPyRE9h [28], alone or fused to mNeonGreen, were described previously [19,38]. Equivalent clones for other *T. cruzi* strains were generated by transfection of the DNA construct pTRIX2-RE9h (TcI-C8, TcI-X10/4, TcIII-Arma18, TcVI-Peru), or by cas9-mediated replacement of the LucRE9h gene with dual reporters, namely LucRE9h::Neon (TcVI-CLBR, TcII-Pot7a, TcIV-X10610) and LucRE9h::mScarlet (TcI-ArePe, TcI-SN3), using the T7 RNA polymerase/cas9 system [38]. *In vitro* epimastigotes were cultivated in supplemented RPMI-1640 medium at 28°C with 150 μg ml⁻¹ G418 or hygromycin B, 5 μg ml⁻¹ puromycin or 10 μg ml⁻¹ blastidicin as appropriate. Metacyclic trypomastigotes (MTs) from stationary phase cultures were used to infect MA104 monkey kidney epithelial cell monolayers in MEM media + 5% FBS at 37°C and 5% CO₂. Tissue culture trypomastigotes (TCTs) were obtained from the supernatant of infected cells after 5 to 21 days, depending on the parasite strain.

**Animals and infections**

Female BALB/c and C3H/HeN mice, postnatal days 42–56, were purchased from Charles River (UK). Female CB17 SCID mice were bred in-house. All mice were housed on a 12 h
light/dark cycle, with food and water available *ad libitum* unless otherwise stated. Mice were maintained under specific pathogen-free conditions in individually ventilated cages.

SCID mice were infected with up to $5 \times 10^6$ *in vitro*-derived TCTs in 0.2 ml PBS via i.p. injection. All infected SCID mice developed fulminant infections and were euthanised at or before humane end-points. Blood trypomastigotes (BTs) were derived from parasitaemic SCID mouse blood directly or after enrichment, achieved by allowing blood samples to settle for 1 h at 37˚C. BALB/c and C3H mice were infected by i.p. injection of $10^3$ or $10^4$ BTs or TCTs depending on the experiment.

At experimental end-points, mice were sacrificed by ex-sanguination under terminal anaesthesia (Euthatal/Dolethal 60 mg kg$^{-1}$, i.p.) or by cervical dislocation. Organs and tissues of interest were excised, imaged (see below) and either snap-frozen, fixed in 10% Glyo-Fixx (Shandon) or transferred to ice-cold DMEM media. The weight of organs and tissues of interest were recorded.

**Total GI transit time assay**

Mice were gavaged p.o. with 200 μl of 6% w/v Carmine red dye solution in 0.5% methyl cellulose mixed in distilled water and returned to their home cage. After 75 min, mice were individually separated into containers and the time of excretion of the first red faecal pellet was recorded. A maximum assay cut-off time of 4 h was implemented. Total intestinal transit time was calculated as the time taken from gavage to output of the first red pellet.

**In vivo bioluminescence imaging**

Mice were injected with 150 mg kg$^{-1}$ D-luciferin i.p., then anaesthetised using 2.5% (v/v) gaseous isoflurane in oxygen. After 10–20 min, bioluminescence imaging was performed using an IVIS Lumina II or Spectrum system (PerkinElmer), with acquisition time and binning adjusted according to signal intensity. Mice were revived and returned to cages after imaging. To estimate parasite burden in live mice, regions of interest (ROIs) were drawn to quantify bioluminescence expressed as total flux (photons/second) [18,19]. The detection threshold was determined using uninfected control mice. All bioluminescence data were analysed using LivingImage v4.7.3.

**Ex vivo bioluminescence imaging**

Mice were injected with 150 mg kg$^{-1}$ D-luciferin i.p. 5–7 min before euthanasia. Trans-cardiac perfusion was performed with 10 ml of 0.3 mg ml$^{-1}$ D-luciferin in PBS. Tissues and organs of interest (typically lymph nodes, heart, spleen, skeletal muscle, GI tract and associated mesenteries) were collected and soaked in PBS containing 0.3 mg ml$^{-1}$ D-luciferin. Bioluminescence imaging was performed as above. To quantify parasite load as a measure of infection intensity, bioluminescence was calculated by outlining ROIs on each sample and expressed as radiance (photons second$^{-1}$ cm$^{-2}$ sr$^{-1}$). Fold change in radiance was determined by comparing samples from infected mice with the equivalent tissues from uninfected, age-matched control mice. To determine the detection threshold, fold change in radiance of empty ROIs on images from infected mice was compared with matching empty ROIs on images from uninfected controls [18].

**Fluorescent tracer transit assay**

Mice were fasted (or not) for 2 or 4 h before euthanasia. They were administered FITC-conjugated 70 kDa dextran (100 μl, 5 mg ml$^{-1}$ d.H$_2$O) or Rhodamine-conjugated 70 kDa dextran...
(100 µL, 10 mg ml⁻¹ dH₂O) by oral gavage 5, 45 or 90 min before euthanasia to target the stomach, small or large intestine transit, respectively. As an extension of the ex vivo bioluminescence necropsy (see above), fluorescence images were obtained using excitation filters set at 465/535 nm and emission filters at 502/583 nm for FITC/Rhodamine (f-stop: 16, exposure: 2 s). The relative fluorescence of the tracers was measured from the images by drawing ROIs using LivingImage 4.7.3 software. The GI tract images starting from the stomach to the colon were cut digitally in 15 equal segments and the centre of mass (geometric centre) of the signals were determined. The geometric centre was calculated using the following equation, GC = ∑ (% of total fluorescent signal per segment * segment number) / 100) [65].

Faecal analyses
The colon tissue was separated and cleaned externally with PBS. The faecal pellets were gently removed from the lumen of the colon, counted and the combined wet weight was recorded. The faecal pellets were collected into a 12-well plate and left to dry in a laminar flow cabinet overnight. The dry weight was then recorded and the percent water content was estimated as the difference between wet and dry weights.

Histopathology and Immunohistochemistry
Paraffin-embedded, fixed tissue blocks were prepared and 3–5 µm sections were stained with haematoxylin and eosin as described [19,32]. For tubulin β-3 immunohistochemistry, sections were subjected to heat-induced epitope retrieval by incubation in 10 mM sodium citrate, 0.05% Tween20 for 30 min at 95˚C then cooled and rinsed in distilled water. Sections were blocked with 10% sheep serum and 1% BSA in TBS for 30 min then incubated at 4˚C overnight with 1 µg ml⁻¹ rabbit polyclonal anti-tubulin β-3 IgG (Biolegend) and 1% BSA in TBS. Sections were then washed with 0.025% Triton X-100 in TBS and endogenous peroxidase activity was quenched with 3% H₂O₂ for 30 min. Bound primary antibody was labelled with excess volume of HRP polymer anti-rabbit IgG reagent (Vector Labs) with 1% BSA in TBS for 30 min. Slides were then washed as previously and incubated with DAB (Thermo) for 5 min. Sections were counterstained with haematoxylin and mounted with DPX.

Images were acquired using a Leica DFC295 camera attached to a Leica DM3000 microscope. For analysis of inflammation, nuclei were counted automatically using the Leica Application Suite V4.5 software (Leica). DAB intensity was analysed as integrated density in ImageJ.

Immunofluorescence analysis
Colon tissues were transferred into ice-cold DMEM after necropsy. Tissues were cut open along the mesentery line, rinsed with PBS, then stretched and pinned on Sylgard 184 plates. The mucosal layer was peeled away using forceps under a dissection microscope and the remaining muscularis wall tissue was fixed in paraformaldehyde (4% w/v in PBS) for 45 min at room temperature. Tissues were washed with PBS for up to 45 min at room temperature and permeabilised with PBS containing 1% Triton X-100 for 2 h, followed by blocking for 1 h (10% sheep serum in PBS containing 1% Triton X-100). Tissues were incubated with primary antibodies (mouse anti-HuC/D IgG clone 16A11 at 1:200 [Thermofisher], rabbit polyclonal anti-tubulin β-3 IgG at 1:500 [Biolegend]) in PBS containing 1% Triton X-100 for 48 h at 4˚C. Tissues were washed with PBS, then incubated with secondary IgG (goat anti-mouse AlexaFluor-546, goat anti-rabbit AlexaFluor-633, both 1:500, ThermoFisher) in PBS containing 1% Triton X-100 for 2 h and counterstained with Hoechst 33342 (1:10 000) at room temperature. To assess antibody specificity, control tissues were incubated without the primary antibody. Tissues were mounted on glass slides using FluorSave mounting medium (Merck).
Whole mounts were examined and imaged with a LSM880 confocal microscope using a 40X objective (Zeiss, Germany). Images were captured as Z-stack scans of 21 digital slices with an interval of 1 μm optical thickness. Five Z-stacks were acquired per region (proximal, mid and distal colon), per animal. Cell counts were performed on Z-stacks after compression into a composite image using the cell counter plug-in of FIJI software. Neuronal density was calculated as the number of HuC/D\(^{+}\) neuron cell bodies per field of view. HuC/D signal was associated with high background outside ganglia in samples from infected mice, attributed to binding of the secondary anti-mouse IgG to endogenous IgG, so ENS-specific analysis was aided by anti-TuJ1 co-labelling and assessment of soma morphology. The number of intact ganglia in each myenteric plexus image was also counted, along with number of HuC/D\(^{+}\) neurons per ganglia.

**RT-qPCR**

Colon tissue samples were snap frozen on dry ice and stored at −70˚C. For RNA extraction, samples were thawed and homogenised in 1 ml Trizol (Invitrogen) per 30–50 mg tissue using a Precellys 24 homogeniser (Bertin). To each sample, 200 μl of chloroform was added and mixed by vortex after which the phases were separated by centrifugation at 13,000 g at 4˚C. RNA was extracted from the aqueous phase using the RNeasy Mini Kit (Qiagen) with on-column DNase digestion as per manufacturer’s protocol. The quantity and quality of RNA was assessed using Qubit Fluorimeter (Thermofisher). cDNA was synthesised from 1 μg of total RNA using Superscript IV VILO mastermix (Invitrogen), as per manufacturer’s protocol, in reaction volumes of 20 μl. A final cDNA volume of 100 μl was made by adding RNase-free DEPC water (1:5 dilution) and stored at −20˚C until further use. qPCR reactions contained 4 μl of cDNA (1:50 dilution) and 200 nM of each primer (S1 Table) and QuantiTect SYBR Green PCR master mix (Qiagen) or SensiFAST SYBR Hi-ROX kit (Bioline). Reactions were run using Applied Biosystems 7500 fast RT-PCR machine (Thermofisher) as per manufacturer’s protocol. Data were analysed by the ΔΔCt method [66] using murine Gapdh as the endogenous control gene.

**Statistics**

Individual animals were used as the unit of analysis. No blinding or randomisation protocols were used. Statistical differences between groups were evaluated using unpaired two-tailed Student’s t-test or one-way ANOVA with Tukey’s post-hoc correction for multiple comparisons. Pearson correlation analyses was used to evaluate relationships between variables. These tests were performed in GraphPad Prism v.8 or R v3.6.3. Differences of \( p < 0.05 \) were considered significant.

**Supporting information**

S1 Fig. Gastrointestinal transit dysfunction screen in mice infected with different strains of *T. cruzi*. Data are gastrointestinal (GI) transit times at indicated weeks post-infection (p.i.) for C3H/HeN mice in the following infection groups: naive control (\( n = 4–6 \)), Tcl-ArePe (\( n = 1–4 \)), Tcl-SN3 (\( n = 4 \)), Tcl-SylvioX10/4 (\( n = 4 \)) and Tcl-C8 (\( n = 4 \)), Tcl-Pot7a (\( n = 4 \)), TclII-Arma18 (\( n = 3–4 \)), TclIV-X10610 (\( n = 4 \)) and TclVI-Peru (\( n = 3 \)).

(TIF)

S2 Fig. *Ex vivo* analysis of parasite tissue distributions for Tcl-SN3, Tcl-ArePe, TclIII-Arma18 and TclVI-Peru strains of *T. cruzi*. A. Bioluminescence signal intensity (blue, low, to red, high) in tissue samples from chronically infected C3H/HeN mice. Samples, from...
top left to right, lung, heart, genito-urinary system, liver, GI mesentery, peritoneum, skeletal muscle, visceral adipose, large intestine, small intestine, stomach and oesophagus. B. Frequency of parasite detection in the indicated organs/tissues. TcI-SN3 n = 4, TcI-ArePe n = 4, TcIII-Arma18 n = 3, TcVI-Peru n = 2.

S3 Fig. Anatomical measures of gastrointestinal T. cruzi infection mouse models. A. Body weights of naive control (n = 3–10), TcI-JR (n = 5–22) and TcVI-CLBR (n = 5–20) infected C3H/HeN (left) and BALB/c mice (right) vs. days post-infection (p.i.). B. Bar plots show length of small intestine and colon of control and TcI-JR C3H/HeN mice at 3 (n = 24 per group), 6 (n = 27 per group) and 30 (n = 5 per group) weeks p.i. Data are expressed as mean ± SEM.

S4 Fig. Fluorescent tracer imaging assay for gastrointestinal (GI) transit in high inoculum acute T. cruzi infection. Schematic diagram of a mouse receiving oral gavage of a green fluorescent marker, FITC-conjugated 70 kDa dextran, 60 or 120 or 180 minutes prior to termination to trace localised GI transit delay during acute infection. Quantification of FITC-dextran fluorescence in different parts of the GI tract (SI 1–SI 10: small intestine scored into 10 equal sections, proximal to distal) of naive control and TcI-JR C3H/HeN (n = 4 per group) mice at 3 weeks post-infection. All mice in this experiment were infected with a high inoculum of TcI-JR parasites (10⁴). Data are expressed as mean ± SEM.

S5 Fig. Comparison of colonic transit dysfunction in different models of experimental digestive Chagas disease. Faecal output analyses are expressed as faecal pellet count, wet and dry pellet weight at 30 weeks post-infection (p.i.) in the following groups: naive control (n = 7–11), TcI-JR (n = 5–11), TcI-SN3 (n = 4), TcI-ArePe (n = 1), TcIII-Arma18 (n = 3), TcVI-Peru (n = 3) and TcVI-CLBR (n = 4–5).

S6 Fig. Myenteric neuronal plexus lesions in T. cruzi infection. Colon tissue samples from C3H mice with chronic TcI-JR infections were cut as transverse cross-sections and images are oriented to show the mucosa above the smooth muscle layers and serosa at the lower edge. Acellular structures (arrows) within myenteric plexus ganglia that are refractory to staining by the indicated method. 400X magnification.

S7 Fig. Chronic phase colonic T. cruzi infection foci of TcI-SN3 parasites in the ENS. Representative immunofluorescent z-stack confocal images of whole-mount colonic muscularis from C3H mice chronically infected with fluorescent TcI-SN3 (mScarlet⁺) parasites. Image shows the localisation of TcI-SN3 parasites (red) in the submucosal layer of the ENS stained with anti-TuJ1 (white). DAPI (cyan) shows DNA and white circle indicates DNA of the parasite nest. Images were taken at 400X magnification, scale bar = 50 μm.

S1 Table. Quantitative PCR target gene and primer information.

Acknowledgments

We thank Hernán Carrasco, Michael Miles, Manuel Sánchez-Moreno, Omar Triana and Matthew Yeo for sharing parasite strains and the LSHTM Biological Services Facility staff for technical support and animal husbandry.
Author Contributions

Conceptualization: Conor J. McCann, John M. Kelly, Michael D. Lewis.

Formal analysis: Archie A. Khan, Harry C. Langston, Michael D. Lewis.

Funding acquisition: Michael D. Lewis.

Investigation: Archie A. Khan, Harry C. Langston, Fernanda C. Costa, Michael D. Lewis.

Methodology: Archie A. Khan, Fernanda C. Costa, Martin C. Taylor, Conor J. McCann, Michael D. Lewis.

Resources: Francisco Olmo, Martin C. Taylor, Conor J. McCann, John M. Kelly, Michael D. Lewis.

Supervision: John M. Kelly, Michael D. Lewis.

Validation: Archie A. Khan, Francisco Olmo, Martin C. Taylor, Michael D. Lewis.

Visualization: Archie A. Khan, Harry C. Langston, Michael D. Lewis.

Writing – original draft: Archie A. Khan, Michael D. Lewis.

Writing – review & editing: Archie A. Khan, Harry C. Langston, Fernanda C. Costa, Francisco Olmo, Martin C. Taylor, Conor J. McCann, John M. Kelly, Michael D. Lewis.

References

1. Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet. 2010; 375(9723):1388–402. https://doi.org/10.1016/S0140-6736(10)60061-X PMID: 20399979

2. Iantorno G, Bassotti G, Kogan Z, Lumi CM, Cabanne AM, Fisogni S, et al. The enteric nervous system in chagasic and idiopathic megacolon. Am J Surg Pathol. 2007; 31(3):460–8. https://doi.org/10.1097/01.pas.0000213371.79300.a8 PMID: 17325489

3. Meneghelli UG. Chagasic enteropathy. Rev Soc Bras Med Trop. 2004; 37(3):252–60. https://doi.org/10.1590/s0003-86822004000300012 PMID: 15330067

4. Rassi A, de Rezende JM, Luquetti AO, Rassi A. Clinical phases and forms of Chagas disease. In: Tellieria J, Tibayrenc M, editors. American Trypanosomiasis Chagas Disease (Second Edition). London: Elsevier; 2017. p. 653–66.

5. Bern C. Antitrypanosomal Therapy for Chronic Chagas’ Disease. New Engl J Med. 2011; 364(26):2527–34. https://doi.org/10.1056/NEJMct1014204 PMID: 21714649

6. Ribeiro I, Sevcisk AM, Alves F, Diap G, Don R, Harhay MO, et al. New, improved treatments for Chagas disease: from the R&D pipeline to the patients. PLoS Negl Trop Dis. 2009; 3(7):e484. https://doi.org/10.1371/journal.pntd.0000484 PMID: 19682163

7. Köberle F. Chagas’ disease and Chagas’ syndromes: the pathology of American trypanosomiasis. Adv Parasitol. 1968; 6(63):63–116. https://doi.org/10.1016/s0065-308x(08)60472-8 PMID: 4239747

8. de Oliveira RB, Troncon LE, Dantas RO, Menghelli UG. Gastrointestinal manifestations of Chagas’ disease. Am J Gastroenterol. 1998; 93(6):884–9. https://doi.org/10.1111/j.1572-0241.1998.270_r.x PMID: 9947012

9. Arantes RM, Marche HH, Bahia MT, Cunha FQ, Rossi MA, Silva JS. Interferon-gamma-induced nitric oxide causes intrinsic intestinal denervation in Trypanosoma cruzi-infected mice. Am J Pathol. 2004; 164(4):1361–1368. https://doi.org/10.1016/s0002-9440(10)63222-1 PMID: 15039223

10. Adad SJ, Andrade DCdS, Lopes ER, Chapadere E. Contribuição ao estudo da anatomia patológica do megaesôfago chagásico. Rev I Med Trop. 1991; 33:443–50.

11. Vago AR, Macedo AM, Adad SJ, Reis DaA, Corrêa-Oliveira R. PCR detection of Trypanosoma cruzi DNA in oesophageal tissues of patients with chronic digestive Chagas’ disease. Lancet. 1996; 348(9031):891–2. https://doi.org/10.1016/S0140-6736(05)64761-7 PMID: 8626826

12. Vago AR, Silva DM, Adad SJ, Correa-Oliveira R, d’Avila Reis D. Chronic Chagas disease: presence of parasite DNA in the esophagus of patients without megaesophagus. Trans R Soc Trop Med Hyg. 2003; 97(3):306–9. https://doi.org/10.1016/s0035-9203(03)90155-6 PMID: 15228249
13. Corbett CE, Ribeiro U, Jr., Prianti MG, Habr-Gama A, Okumura M, Gama-Rodrigues J. Cell-mediated immune response in megacolon from patients with chronic Chagas' disease. Dis Colon Rectum. 2001; 44(7):993–8. https://doi.org/10.1007/BF02235488 PMID: 11496080

14. Lages-Silva E, Crema E, Ramirez LE, Macedo AM, Pena SD, Chiarle E. Relationship between Trypanosoma cruzi and human chagasic megasophagus: blood and tissue parasitism. Am J Trop Med Hyg. 2001; 65(5):435–41. https://doi.org/10.4269/ajtmh.2001.65.435 PMID: 11716095

15. da Silveira ABM, Arantes RME, Vago AR, Lemos EM, Adad SJ, Correa-Oliveira R, et al. Comparative study of the presence of Trypanosoma cruzi kDNA, inflammation and denervation in chagastic patients with and without megasophagus. Parasitology. 2005; 131(05):627–34. https://doi.org/10.1017/S0031182005008061 PMID: 16255821

16. da Silveira ABM, Lemos EM, Adad SJ, Correa-Oliveira R, Furness JB, D’Avila Reis D. Megacolon in Chagas disease: a study of inflammatory cells, enteric nerves, and glial cells. Hum Pathol. 2007; 38(8):1256–64. https://doi.org/10.1016/j.humpath.2007.01.020 PMID: 17490721

17. de Castro Côbo de E, Silveira TP, Micheletti AM, Crema E, Adad SJ. Research on Trypanosoma cruzi and Analysis of Inflammatory Infiltrate in Esophagus and Colon from Chronic Chagasic Patients with and without Mega. J Trop Med. 2012; 2012:232646. https://doi.org/10.1155/2012/232646 PMID: 22131997

18. Lewis MD, Francisco AF, Taylor MC, Burrell-Saward H, McLatchie AP, Miles MA, et al. Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection. Cell Microbiol. 2014; 16(9):1265–300. https://doi.org/10.1111/cmi.12297 PMID: 24712539

19. Lewis MD, Francisco AF, Taylor MC, Jayawardhana S, Kelly JM. Host and parasite genetics shape a link between Trypanosoma cruzi infection dynamics and chronic cardiomyopathy. Cell Microbiol. 2016; 18(10):1429–43. https://doi.org/10.1111/cmi.12584 PMID: 26918803

20. Silberstein E, Serna C, Frangoso SP, Nagarkatti R, Debrabant A. A novel nanoluminescence-based system to monitor Trypanosoma cruzi infection in mice by bioluminescence imaging. PLoS ONE. 2018; 13(4):e0195879. https://doi.org/10.1371/journal.pone.0195879 PMID: 29872535

21. Francisco AF, Lewis MD, Jayawardhana S, Taylor MC, Chatelain E, Kelly JM. The limited ability of posaconazole to cure both acute and chronic Trypanosoma cruzi infections revealed by highly sensitive in vivo imaging. Antimicrob Agents Chemother. 2015; 59(8):4653–61. https://doi.org/10.1128/AAC.00520-15 PMID: 26014936

22. Santi-Rocca J, Fernandez-Cortes F, Chilión-Marinas C, González-Rubio M-L, Martin D, Gironès N, et al. A multi-parametric analysis of Trypanosoma cruzi infection: common pathophysiological patterns beyond extreme heterogeneity of host responses. Sci Rep. 2017; 7(1):1–12. https://doi.org/10.1038/s41598-016-0028-x

23. Laranjeira C, Sandgren K, Kessaris N, Richardson W, Potocnik A, Vanden Berghe P, et al. Gial cells in the mouse enteric nervous system can undergo neurogenesis in response to injury. J Clin Invest. 2011; 121(9):3412–24. https://doi.org/10.1172/JCI58200 PMID: 21865647

24. Kulikarni S, Micci M-A, Leser J, Shin C, Tang S-C, Fu Y-Y, et al. Adult enteric nervous system in health is maintained by a dynamic balance between neuronal apoptosis and neurogenesis. Proc Natl Acad Sci USA. 2017; 114(18):E3709–E18. https://doi.org/10.1073/pnas.1619406114 PMID: 28420791

25. Muller PA, Koscsó B, Rajani Gaurav M, Stevanovic K, Berres M-L, Hashimoto D, et al. Crosstalk between Muscularis Macrophages and Enteric Neurons Regulates Gastrointestinal Motility. Cell. 2014; 158(2):300–13. https://doi.org/10.1016/j.cell.2014.04.050 PMID: 25036630

26. Gabanyi I, Muller PA, Feighery L, Oliveira Thiago Y, Costa-Pinto Frederico A, Mucida D. Neuro-immune Interactions Drive Tissue Programming in Intestinal Macrophages. Cell. 2016; 164(3):378–91. https://doi.org/10.1016/j.cell.2015.12.023 PMID: 26777404

27. do Carmo Neto JR, Vinicius da Silva M, Braga YLL, Florencio da Costa AW, Fonseca SG, Nagib PRA, et al. Correlation between intestinal BMP2, IFNy, and neural death in experimental infection with Trypanosoma cruzi. PLoS ONE. 2021; 16(2):e0246692. https://doi.org/10.1371/journal.pone.0246692 PMID: 33561140

28. Branchini BR, Ablamsky DM, Davis AL, Southworth TL, Butler B, Fan F, et al. Red-emitting luciferases for bioluminescence reporter and imaging applications. Anal Biochem. 2010; 396(2):290–7. https://doi.org/10.1016/j.ab.2010.09.009 PMID: 19748472

29. Machado CA, Ayala FJ. Nucleotide sequences provide evidence of genetic exchange among distantly related lineages of Trypanosoma cruzi. Proc Natl Acad Sci USA. 2001; 98(13):7396–401. https://doi.org/10.1073/pnas.12187198 PMID: 11416213

30. Westenberger SJ, Barnabé C, Campbell DA, Sturm NR. Two hybridization events define the population structure of Trypanosoma cruzi. Genetics. 2005; 171(2):527–43. https://doi.org/10.1534/genetics.104.038745 PMID: 15998728
31. Lewis MD, Llewellyn MS, Yeo M, Acosta N, Gaunt MW, Miles MA. Recent, Independent and Anthropogenic Origins of *Trypanosoma cruzi* Hybrids. PLoS Negl Trop Dis. 2011; 5(10):e1363. https://doi.org/10.1371/journal.pntd.0001363 PMID: 22022633

32. Lewis MD, Francisca AF, Jayawardhana S, Langston H, Taylor MC, Kelly JM. Imaging the development of chronic Chagas disease after oral transmission. Sci Rep. 2018; 8(1):11292. https://doi.org/10.1038/s41598-018-29564-7 PMID: 30050153

33. Nascimento R, Martins P, Duarte J, d’Ávila Reis D. Decrease of Nitrergic Innervation in the Esophagus of Patients with Chagas Disease: Correlation with Loss of Interstitial Cells of Cajal. J Int J Pathol Clin Res. 2017; 3:059.

34. Dickson EJ, Heredia DJ, McCann CJ, Hennig GW, Smith TK. The mechanisms underlying the generation of the colonic migrating motor complex in both wild-type and nNOS knockout mice. Am J Physiol Gastrointest Liver Physiol. 2010; 298(2):G222–G32. https://doi.org/10.1152/ajpgi.00399.2009 PMID: 1995818

35. McCann CJ, Cooper JE, Natarajan D, Jevans B, Burnett LE, Burns AJ, et al. Transplantation of enteric nervous system stem cells rescues nitric oxide synthase deficient mouse colon. Nat Commun. 2017; 8:15937. https://doi.org/10.1038/ncomms15937 PMID: 28671186

36. Rivera LR, Poole DP, Thacker M, Furness JB, Motility. The involvement of nitric oxide synthase neurons in enteric neuropathies. Neurogastroenterol Motil. 2011; 23(11):980–8. https://doi.org/10.1111/j.1365-2982.2011.01780.x PMID: 21895878

37. Ward AI, Lewis MD, Khan AA, McCann CJ, Francisco AF, Jayawardhana S, et al. In Vivo Analysis of *Trypanosoma cruzi* Persistence Foci at Single-Cell Resolution. mBio. 2020; 11(4):e01242–20. https://doi.org/10.1128/mBio.01242-20 PMID: 32753495

38. Costa FC, Francisco AF, Jayawardhana S, Calderano SG, Lewis MD, Olmo F, et al. Expanding the toolbox for *Trypanosoma cruzi*: A parasite line incorporating a bioluminescence-fluorescence dual reporter and streamlined CRISPR/Cas9 functionality for rapid in vivo localization and phenotyping. PLoS Negl Trop Dis. 2018; 12(4):e0006388. https://doi.org/10.1371/journal.pntd.0006388 PMID: 29608569

39. Da Silveira A, Freitas M, De Oliveira E, Neto S, Luquetti A, Furness J, et al. Neuronal plasticity of the enteric nervous system is correlated with chagasic megacolon development. Parassitologia. 2008; 135 (11):1337–42. https://doi.org/10.1017/S0031182008004770 PMID: 18664306

40. Koberle F. Enteromegaly and Cardiomegaly in Chagas Disease. Gut. 1963; 4(4):399–405.

41. Ko¨ berle F. Enteromegaly and Cardiomegaly in Chagas Disease. Gut. 1963; 4(4):399–405.

42. Oda JY, Bele ´ m MO, Carlos TM, Gouveia R, Luchetti BFC, Moreira NM, et al. Myenteric neuroprotective role of aspirin in acute and chronic experimental infections with *Trypanosoma cruzi*. Neurogastroenterol Motil. 2017; 29(10):1–13. https://doi.org/10.1111/nmo.13102 PMID: 28524628

43. Malfrino LB, Liberti EA, Watanabe I, De Souza RR. Morphometry and acetylcholinesterase activity of the myenteric neurons of the mouse colon in the chronic phase of experimental *Trypanosoma cruzi* infection. Am J Trop Med Hyg. 1999; 60(5):721–5. https://doi.org/10.4269/ajtmh.1999.60.721 PMID: 10344641

44. de Oliveira GM, de Melo Medeiros M, da Silva Batista W, Santana R, Araujo-Jorge TC, de Souza AP. Applicability of the use of charcoal for the evaluation of intestinal motility in a murine model of *Trypanosoma cruzi* infection. Parasitol Res. 2008; 102(4):747–50. https://doi.org/10.1007/s00436-007-0829-8 PMID: 18163190

45. de Souza AP, Sieberg R, Li H, Cahill HR, Zhao D, Araujo-Jorge TC, et al. The role of selenium in intestinal motility and morphology in a murine model of *Trypanosoma cruzi* infection. Parasitol Res. 2010; 106 (6):1293–8. https://doi.org/10.1007/s00436-010-1794-1 PMID: 20195635

46. Lopes ER, Rocha A, Meneses AC, Lopes MA, Fatureto MC, Lopes GP, et al. Prevalência de megas em necrópsias realizadas no triângulo mineiro no período de 1954 a 1988. Rev Soc Bras Med Trop. 1989; 22(4):211–5. https://doi.org/10.1590/s0037-86821989004000008 PMID: 2518668
49. Osman KL, Kohlberg S, Mok A, Brooks R, Lind LA, McCormack K, et al. Optimizing the Translational Value of Mouse Models of ALS for Dysphagia Therapeutic Discovery. Dysphagia. 2020; 35(2):343–59. https://doi.org/10.1007/s00455-019-10034-9 PMID: 31300881

50. Hugenholtz F, de Vos WM. Mouse models for human intestinal microbiota research: a critical evaluation. Cell Mol Life Sci. 2018; 75(1):149–60. https://doi.org/10.1007/s00018-017-2693-8 PMID: 29124307

51. Jd Rezende. Chagasic mega syndromes and regional differences. New Approaches in American trypanosomiasis research Pan Am Health Org Sci Publ. 1975; 318:195–205.

52. Chatelain E, Scandale I. Animal models of Chagas disease and their translational value to drug development. Expert Opin Drug Discov. 2020; 15(12):1381–402. https://doi.org/10.1080/17460441.2020.1806233 PMID: 32812830

53. Miles M, Cedillos R, Povoa M, de Souza A, Prata A, Macedo V. Do radically dissimilar Trypanosoma cruzi strains (zymodemes) cause Venezuelan and Brazilian forms of Chagas’ disease? Lancet. 1981; 317(8234):1338–40. https://doi.org/10.1016/s0140-6736(81)92518-6 PMID: 6113312

54. Messenger LA, Miles MA, Bern C. Between a bug and a hard place: Trypanosoma cruzi genetic diversity and the clinical outcomes of Chagas disease. Expert Rev Anti Infect Ther. 2015; 13(8):995–1029. https://doi.org/10.1586/14787210.2015.1056158 PMID: 26162928

55. Panesso-Gómez S, Pavia P, Rodríguez-Mantilla IE, Lasso P, Orozco LA, Cuellar A, et al. Trypanosoma cruzi Detection in Colombian Patients with a Diagnosis of Esophageal Achalasia. Am J Trop Med Hyg. 2018; 98(3):717–23. https://doi.org/10.4269/ajtmh.17-0417 PMID: 29405099

56. Flórez O, Esper J, Higuera S, Barraza MF, Cabrera HB, Mantilla JC, et al. Chagasic megacolon associated with Trypanosoma cruzi I in a Colombian patient. Parasitol Res. 2010; 107(2):439–42. https://doi.org/10.1007/s00436-010-1874-2 PMID: 20502919

57. Sánchez-Guillén MC, López-Colombo A, Ordóñez-Toquero G, Gomez-Albino I, Ramos-Jimenez J, Torres-Rasgado E, et al. Clinical forms of Trypanosoma cruzi infected individuals in the chronic phase of Chagas disease in Puebla, Mexico. Mem Inst Oswaldo Cruz. 2006; 101(7):733–40. https://doi.org/10.1590/s0074-02762006000700005 PMID: 17160280

58. Jabari S, de Oliveira EC, Brehmer A, da Silveira AB. Chagasic megacolon: enteric neurons and related structures. Histochim Cell Biol. 2014; 142(3):235–44. https://doi.org/10.1007/s00418-014-1250-x PMID: 25059649

59. Boesmans W, Lasrado R, Vanden Berge P, Pachnis V. Heterogeneity and phenotypic plasticity of glial cells in the mammalian enteric nervous system. Glia. 2015; 63(2):229–41. https://doi.org/10.1002/glia.22746 PMID: 25161129

60. Hossain E, Khannah S, Dean DA, Wu C, Lostracco-Johnson S, Thomas D, et al. Mapping of host-parasite-microbiome interactions reveals metabolic determinants of tropism and tolerance in Chagas disease. Sci Adv. 2020; 6(30):eaaz2015. https://doi.org/10.1126/sciadv.aaz2015 PMID: 32766448

61. Veiga-Fernandes H, Pachnis V. Neuroimmune regulation during intestinal development and homeostasis. Nat Immunol. 2017; 18(2):116–22. https://doi.org/10.1038/nri.3634 PMID: 28092371

62. Pérez-Mazliah D, Ward Al, Lewis MD. Host-parasite dynamics in Chagas disease from systemic to hyper-local scales. Parasite Immunol. 2021; 43(2):e12786. https://doi.org/10.1111/pim.12786 PMID: 32799361

63. Yoo BB, Mazmanian SK. The Enteric Network: Interactions between the Immune and Nervous Systems of the Gut. Immunity. 2017; 46(6):910–26. https://doi.org/10.1016/j.immuni.2017.05.011 PMID: 28636959

64. Köberle F. The causation and importance of nervous lesions in American trypanosomiasis. B World Health Organ. 1970; 42(5):739–43. PMID: 4988694

65. Miller MS, Galligan JJ, Burks TF. Accurate measurement of intestinal transit in the rat. J Pharmacol Methods. 1981; 6(3):211–7. https://doi.org/10.1016/0160-5402(81)90110-8 PMID: 7329070

66. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008; 3:1101. https://doi.org/10.1038/nprot.2008.73 PMID: 18546601